ProJenX
Latest round
- Series A
Last raised
- Nov 2023
Total raised
- $20M
Investors
- 1
About ProJenX
Founded in 2021 and based in New York, US, ProJenX, Inc. operates as a clinical-stage biotechnology company that researches and develops therapies for ASL and other neurodegenerative diseases with Prosetin, a MAP4K inhibitor therapy. The company was co-founded by Arie Zask, Emily Lowry, Hynek Wichterle, and Brent Stockwell. In November 2023, ProJenX, Inc. The company is developing novel, brain-penetrant therapies for the treatment of debilitating brain diseases, with an initial focus on ALS. The company's aims to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other neurodegenerative diseases.
Who invested in ProJenX
1 investor across 2 rounds
See all investors in ProJenX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ProJenX
Who invested in ProJenX?
ProJenX has 1 investor on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ProJenX raised?
ProJenX has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did ProJenX last raise money?
ProJenX's most recent round on record is a Series A, in Nov 2023.
What does ProJenX do?
Founded in 2021 and based in New York, US, ProJenX, Inc.
Where is ProJenX headquartered?
ProJenX is headquartered in US.
Which VCs invest in companies like ProJenX?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at ProJenX's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like ProJenX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.